Literature DB >> 10783214

Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension.

S Ciaroni1, L Cuenoud, A Bloch.   

Abstract

BACKGROUND: The risk factors involved in the onset of atrial fibrillation (AF) are well known, but the predictive clinical and paraclinical parameters for the onset of AF in hypertensive patients have not been investigated specifically. METHODS AND
RESULTS: We retrospectively analyzed 97 consecutive patients with hypertension and no known history of AF or cardiovascular events who attended the cardiology outpatient clinic. The analysis was based on clinical data, the noninvasive ambulatory 24-hour measurement of blood pressure (AMBP), a standard 12-lead electrocardiogram, and a Doppler echocardiogram. After a mean follow-up of 25 +/- 3 months, 19 (19. 5%) patients had AF, 3 (15.8%) of whom had a cerebrovascular accident. The patients with AF were older than the others and their AMBP showed higher mean systolic diurnal and nocturnal blood pressures, though no differences in the clinical blood pressure readings were present. On the electrocardiogram, the maximum duration of the P wave and its dispersion were more prolonged in the patients with AF. On the Doppler echocardiogram, left ventricular mass and left atrial dimension were higher in the patients with AF, and the A-wave velocity of diastolic mitral flow was reduced in these patients. In the multivariate analysis, age (odds ratio 3.28, P <.001), diurnal systolic blood pressure (odds ratio 1.35, P <.01) and nocturnal systolic blood pressure (odds ratio 1.16, P <.01), maximum duration of the P wave (odds ratio 2.09, P <.01), dispersion of the P wave (odds ratio 2.52, P <.001), echocardiographic left ventricular mass (odds ratio 1.43, P <.01), left atrial dimension (odds ratio 2.81, P <.001), and velocity of the A wave (odds ratio 2. 24, P <.01) were independent predictors for the onset of AF. After correction for age, maximum duration of the P wave (odds ratio 1.34, P <.01), dispersion of the P wave (odds ratio 1.63, P <.001), and the velocity of the A wave (odds ratio 1.42, P <.01) remained independent predictors for the onset of AF.
CONCLUSIONS: In patients with hypertension, age and the level of diurnal and nocturnal systolic blood pressures measured by 24-hour AMBP are important independent predictors for the onset of AF. Independent of age, increases in left atrial dimension and left ventricular mass, prolongation of the maximum duration and dispersion of the P wave and reduced A-wave velocity are also predictors for the onset of AF.

Entities:  

Mesh:

Year:  2000        PMID: 10783214     DOI: 10.1016/s0002-8703(00)90012-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  29 in total

1.  Meta-analysis of p-wave dispersion values in healthy individuals: the influence of clinical characteristics.

Authors:  Udi Nussinovitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-01       Impact factor: 1.468

2.  The relationship between P wave dispersion and diastolic dysfunction.

Authors:  Huseyin Gunduz; Emrah Binak; Huseyin Arinc; Ramazan Akdemir; Hakan Ozhan; Ali Tamer; Cihangir Uyan
Journal:  Tex Heart Inst J       Date:  2005

3.  Evaluation of the relationship between atrial septal aneurysm and cardiac arrhythmias via P-wave dispersion and signal-averaged P-wave duration.

Authors:  Onur Sinan Deveci; Kudret Aytemir; Sercan Okutucu; Erol Tulumen; Hakan Aksoy; Ergun Baris Kaya; Banu Evranos; Giray Kabakci; Lale Tokgozoglu; Ali Oto; Hilmi Ozkutlu
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

Review 4.  Atrial fibrillation and heart failure parallels: lessons for atrial fibrillation prevention.

Authors:  David D McManus; Amir Y Shaikh; Fnu Abhishek; Ramachandran S Vasan
Journal:  Crit Pathw Cardiol       Date:  2011-03

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

6.  Longitudinal evaluation of P-wave dispersion and P-wave maximum in children after transcatheter device closure of secundum atrial septal defect.

Authors:  Robert Teodoro Grignani; Kim Martin Tolentino; Dimple Dayaram Rajgor; Swee Chye Quek
Journal:  Pediatr Cardiol       Date:  2015-01-28       Impact factor: 1.655

7.  Does impaired left ventricular relaxation affect P wave dispersion in patients with hypertension?

Authors:  Abdullah Dogan; Mehmet Ozaydin; Cem Nazli; Ahmet Altinbas; Omer Gedikli; Ozan Kinay; Oktay Ergene
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-07       Impact factor: 1.468

8.  Maximum p wave duration and p wave dispersion in adult patients with secundum atrial septal defect: the impact of surgical repair.

Authors:  Umit Guray; Yesim Guray; Burcu Mecit; M Birhan Yilmaz; Hatice Sasmaz; Sule Korkmaz
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

9.  Effects of P-wave dispersion on atrial fibrillation in patients with acute anterior wall myocardial infarction.

Authors:  Merih Baykan; Sükrü Celik; Cevdet Erdöl; Ismet Durmuş; Cihan Orem; Mehmet Küçükosmanoğlu; Remzi Yilmaz
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

10.  P-wave duration and dispersion in obese subjects.

Authors:  Feridun Kosar; Yüksel Aksoy; Fahri Ari; Lezzan Keskin; Ibrahim Sahin
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-01       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.